PLAINSBORO, N.J., Jan. 6, 2020 /PRNewswire/ — Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved Fiasp (insulin aspart injection) 100 u/mL for use as a new mealtime insulin option for children with diabetes.1…Original Article
FDA Approves Fiasp (insulin aspart injection) for the Treatment of Children with Diabetes
